Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — JPM TMT Conference (January 2026)
14 slides from Jasper Therapeutics's conference presentation, Jan 8, 2026
Slide 1: Jasper Therapeutics
Thumbnails Document Outline Attachments Slide 1: Jasper Therapeutics Slide 2 Slide 3 Slide 4 Slide 5 Slide 6 Slide 7 Slide 8 Slide 9 Slide 10 Slide 11 Slide 12 Slide 13 Slide 14 Slide 15 Slide 16 Slide 17 Slide 18 Slide 19 Slide 20: Jasper Therapeutics Find in document… Previous
Slide 2: Jasper Therapeutics BEACON Update January 8, 2026
Next Highlight all Match case Whole words Presentation Mode Open Print Download Current View Go to First Page Go to Last Page Rotate Clockwise Rotate Counterclockwise Text Selection Tool Hand Tool Vertical Scrolling Horizontal Scrolling Wrapped Scrolling No Spreads Odd Spreads Even Spreads Document
Slide 3: Safe Harbor Statements
2BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ONSafe Harbor StatementsForward-L presentation and any accompanying oral presentation (together, this “Presentation”) contain forward-looking statements. All statements contained in this Presentation, including statements rega
Slide 4: BEACON & OLE Data Update
with deep UAS7 reduction and disease control in first 2-4 weeks•Drug clearance near end of 8 week dosing cy related AEs and improved profile for patientsBriquilimab continues to demonstrate rapid and dura additional patients enrolled in the BEACON study–Eight (6 briquilimab + 2 placebo) in Cohort 9.
Slide 5: January 2026 BEACON Study & Data Update
January 2026 BEACON Study & 5BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ON DataUpdate Briquilimab continues to demonstrate rapid and durable clinic Cohort 9.1 patientsreaffirms strong efficacy and safety profile•Mean reduction in UAS7 scores of 31 of effect with CR or w
Slide 6: Rapid and deep reductions in tryptase and sustained UAS7 response
Rapid and deep reductions in tr 7BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ON initial240mgor higher doseData cut-off 2Jan 2026Serum Tryptase (ng/ml)Week024681012Placebo ( (n=5)240mg Q8W (n=6)240mg -> 180mg Q8W (n=13)012468 New 240mg/180mg Q8W data 8BRIQUILIMAB IS AN IN
Slide 7: 240mg/180mg Q8W patients demonstrate rapid and durable response
9BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ONResponse (%)Week01020304050607080901001234 240mg/180mg Q8W patients demonstrate rapid and durable response complete response at week 3 (n=6)Data cut-off 2Jan 2026 10BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR
Slide 8: Safety/tolerability observations
PooledBriquilimab (N=64)4TotalPooled Placebo(N=21) Any TEAE10 (71.4)6 (100)4 (80)3 (50)5 (71.4)6 (100)48 (75)12 (57.1)Any (7.1)10 (0)0 (0)0 (0)0 (0)0 (0)1 (1.6)10 (0)Any TEAE Leading to Discontinuation of IP1 (7.1)10 (0)0 (0)0 (0)1 (14.3)20 (0)2 (3.1)1,20 (0)Any (0)1 (16.7)30 (0)0 (0)0 (0)0 (0)1 (1.
Slide 9: Chronic Urticaria Open Label Extension Study; CIndU OLE clinical responses
Screening/Eligibility•To enroll, patients from BEAC 12BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ON for symptoms to return following dosing (defined as UAS7 ≥16 for CSU, UCT≤12 for CIndU) •OR complete the BEACON/ Objectives/Enrollment Target•Generate additional safety,
Slide 10: CSU show increasing efficacy over time at 180mg Q8W
14BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ON0510152025303501234567891011121314151617181920 CSU show increasing efficacy over time at 180mg Q8W22.4 pt reduction in UAS7 Complete Response rate observed at week 20n=36n=38n=46WeekData cut-off 11 Dec 2025MeanUAS70%10%20%3
Slide 11: Conclusion and Next Steps
Conclusion and Next StepsJeet Mah Briquilimab complete response 17BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ON disease at 12 weeksNote: These observations are derived from separate clinical settings; comparisons across trials are not base & WC at Week 12 (UAS7=0 and UA
Slide 12: Briquilimab demonstrated rapid disease control
18BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVEDFOR ANY INDICATI ONBriquilimab demonstrated rapid disease controlNote: At Week 6 in the BEACON study, patients in the placebo arm were allowed rescue medications.Note: These obse settings; comparisons across trials are not based on head-to-he
Slide 13: Enter the password to open this PDF file. File name: File size:
Enter the password to open this PDF file. Cancel OK File name: - File size: - Title: - Author: - Subject: - Keywords: - Creation Date: - Modification Date: -
Slide 14: PDF Producer: PDF Version: Page Count:
Creator: - PDF Producer: - PDF Version: - Page Count: - Page Size: - Fast Web View: - Close Preparing document for printing… 0% Cancel Choose File No file chosen
Jasper Therapeutics — JPM TMT Conference (January 2026) on 6ix